<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04670679</url>
  </required_header>
  <id_info>
    <org_study_id>ERAS-601-01</org_study_id>
    <nct_id>NCT04670679</nct_id>
  </id_info>
  <brief_title>A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors</brief_title>
  <acronym>FLAGSHP-1</acronym>
  <official_title>An Open-Label, Multi-Center Phase 1/1b Dose Escalation and Expansion Study of ERAS-601 SHP2 Inhibitor as a Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasca, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasca, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To evaluate the safety and tolerability of escalating doses of ERAS-601 when&#xD;
           administered as a monotherapy and in combination with other cancer therapies in study&#xD;
           participants with advanced or metastatic solid tumors.&#xD;
&#xD;
        -  To determine the Maximum Tolerated Dose (MTD) and/or recommended dose (RD) of ERAS-601&#xD;
           when administered as a monotherapy and in combination with other cancer therapies.&#xD;
&#xD;
        -  To characterize the pharmacokinetic (PK) profile of ERAS-601 when administered as a&#xD;
           monotherapy and in combination with other cancer therapies.&#xD;
&#xD;
        -  To evaluate the antitumor activity of ERAS-601 when administered as a monotherapy and in&#xD;
           combination with other cancer therapies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first-in-human, Phase 1/1b, open-label, multicenter clinical study of ERAS-601 as a&#xD;
      monotherapy and in combination with other cancer therapies. The study will commence with dose&#xD;
      escalation of ERAS-601 monotherapy, followed by dose escalation of ERAS-601 in combination&#xD;
      with other cancer therapies. Once the monotherapy MTD and/or RD has been determined, then&#xD;
      dose expansion of ERAS-601 monotherapy may commence with enrollment of study participants&#xD;
      with advanced or metastatic solid tumors harboring specific molecular alterations. Once the&#xD;
      combination therapy MTD and/or RD has been determined, then dose expansion of that&#xD;
      combination may commence with enrollment of study participants with advanced or metastatic&#xD;
      solid tumors harboring specific molecular alterations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLT)</measure>
    <time_frame>Study Day 1 up to Day 29</time_frame>
    <description>Based on toxicities observed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>Study Day 1 up to Day 29</time_frame>
    <description>Based on toxicities observed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended dose (RD)</measure>
    <time_frame>Study Day 1 up to Day 29</time_frame>
    <description>Based on toxicities observed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Assessed up to 24 months from time of first dose</time_frame>
    <description>Incidence and severity of treatment-emergent AEs and serious AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration (Cmax)</measure>
    <time_frame>Study Day 1 up to Day 29</time_frame>
    <description>Maximum plasma concentration of ERAS-601 and cetuximab (if applicable)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to achieve Cmax (Tmax)</measure>
    <time_frame>Study Day 1 up to Day 29</time_frame>
    <description>Time to achieve maximum plasma concentration of ERAS-601 and cetuximab (if applicable)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve</measure>
    <time_frame>Study Day 1 up to Day 29</time_frame>
    <description>Area under the plasma concentration-time curve of ERAS-601 and cetuximab (if applicable)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life</measure>
    <time_frame>Study Day 1 up to Day 29</time_frame>
    <description>Half-life of ERAS-601 and cetuximab (if applicable)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Assessed up to 24 months from time of first dose</time_frame>
    <description>Based on assessment of radiographic imaging per RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Assessed up to 24 months from time of first dose</time_frame>
    <description>Based on assessment of radiographic imaging per RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>Assessed up to 24 months from time of first dose</time_frame>
    <description>Based on assessment of radiographic imaging per RECIST version 1.1</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacodynamic assessment</measure>
    <time_frame>Assessed up to 24 months from time of first dose</time_frame>
    <description>Assessment of phosphorylated ERK (pERK) inhibition in PBMCs or tumor tissue by IHC or immunofluorescence.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Advanced or Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Dose Escalation (Part A): ERAS-601 monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ERAS-601 monotherapy will be administered in sequential ascending doses to study participants with advanced or metastatic solid tumors until unacceptable toxicity, disease progression, or withdrawal of consent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation (Part B): ERAS-601 in combination with cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ERAS-601 will be administered in sequential ascending doses in combination with cetuximab to study participants with advanced or metastatic solid tumors until unacceptable toxicity, disease progression, or withdrawal of consent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion (Part C): ERAS-601 monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ERAS-601 will be administered at the monotherapy recommended dose (as determined from Part A) to study participants with advanced or metastatic solid tumors that harbor specific molecular alterations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion (Part D): ERAS-601 in combination with cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ERAS-601 will be administered with cetuximab at the combination therapy recommended dose (as determined from Part B) to study participants with advanced or metastatic head and neck squamous cell carcinomas (HNSCC) or colorectal cancer (CRC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ERAS-601</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Dose Escalation (Part A): ERAS-601 monotherapy</arm_group_label>
    <arm_group_label>Dose Escalation (Part B): ERAS-601 in combination with cetuximab</arm_group_label>
    <arm_group_label>Dose Expansion (Part C): ERAS-601 monotherapy</arm_group_label>
    <arm_group_label>Dose Expansion (Part D): ERAS-601 in combination with cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Administered via intravenous infusion</description>
    <arm_group_label>Dose Escalation (Part B): ERAS-601 in combination with cetuximab</arm_group_label>
    <arm_group_label>Dose Expansion (Part D): ERAS-601 in combination with cetuximab</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
          -  Willing and able to give written informed consent&#xD;
&#xD;
          -  Have histologically or cytologically confirmed advanced or metastatic solid tumor&#xD;
&#xD;
          -  There is no available standard systemic therapy available for the patient's tumor&#xD;
             histology and/or molecular biomarker profile; or standard therapy is intolerable, not&#xD;
             effective, or not accessible; or patient has refused standard therapy&#xD;
&#xD;
          -  Able to swallow oral medication&#xD;
&#xD;
          -  Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1&#xD;
&#xD;
          -  Adequate cardiovascular, hematological, liver, and renal function&#xD;
&#xD;
          -  Willing to comply with all protocol-required visits, assessments, and procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with a SHP2 inhibitor&#xD;
&#xD;
          -  Documented PTPN11 mutations&#xD;
&#xD;
          -  Is currently receiving another study therapy or has participated in a study of an&#xD;
             investigational agent and received study therapy within 4 weeks of the first dose of&#xD;
             ERAS-601&#xD;
&#xD;
          -  Received prior palliative radiation within 7 days of Cycle 1, Day 1&#xD;
&#xD;
          -  Have primary central nervous system (CNS) disease or known active CNS metastases&#xD;
             and/or carcinomatous meningitis&#xD;
&#xD;
          -  Prior surgery (e.g., gastric bypass surgery, gastrectomy) or gastrointestinal&#xD;
             dysfunction (e.g., Crohn's disease, ulcerative colitis, short gut syndrome) that may&#xD;
             affect drug absorption&#xD;
&#xD;
          -  Active, clinically significant interstitial lung disease or pneumonitis&#xD;
&#xD;
          -  History of thromboembolic or cerebrovascular events â‰¤ 12 weeks prior to the first dose&#xD;
             of study treatment&#xD;
&#xD;
          -  History or current evidence of retinal vein occlusion (RVO) or current risk factors&#xD;
             for RVO&#xD;
&#xD;
          -  Have any underlying medical condition, psychiatric condition, or social situation&#xD;
             that, in the opinion of the Investigator, would compromise study administration as per&#xD;
             protocol or compromise the assessment of AEs&#xD;
&#xD;
          -  Are pregnant or breastfeeding or expecting to conceive or father children within the&#xD;
             projected duration of the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Les Brail, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Development</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erasca Clinical Team</last_name>
    <phone>+1-858-465-6511</phone>
    <email>clinicaltrials@erasca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute (Florida Cancer Specialists)</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute (Tennessee Oncology)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 11, 2020</study_first_submitted>
  <study_first_submitted_qc>December 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SHP2</keyword>
  <keyword>PTPN11</keyword>
  <keyword>solid tumor</keyword>
  <keyword>advanced solid tumor</keyword>
  <keyword>metastatic solid tumor</keyword>
  <keyword>neoplasms</keyword>
  <keyword>solid malignancies</keyword>
  <keyword>targeted therapy</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>CRC</keyword>
  <keyword>head and neck squamous cell carcinoma</keyword>
  <keyword>HNSCC</keyword>
  <keyword>molecular alterations</keyword>
  <keyword>cetuximab</keyword>
  <keyword>Erbitux</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

